Skip to main content
SpringerLink
Log in

Immunotherapy with autologous antigen presenting cells for the treatment of androgen independent prostate cancer

  • Topic Paper
  • Published:
World Journal of Urology Aims and scope Submit manuscript

Abstract

Prostate cancer is an excellent target for an active vaccine-based approach based on the fact that prostate cancer cells express unique proteins which serve as highly specific targets. APC8015 (Provenge) is one such investigational therapeutic vaccine that uses autologous antigen presenting cells (APCs) loaded with a recombinant fusion protein of prostatic acid phosphatase linked to a molecule that specifically targets a receptor expressed on the surface of human APCs. Clinical trial outcomes have demonstrated activity in patients with androgen independent prostate cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Schmielau J, Finn OJ (2001) Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of T-cell function in advanced cancer patients. Cancer Res 61:4756–4760

    CAS  PubMed  Google Scholar 

  2. Zhang H et al. (2003) Concordant down-regulation of proto-oncogene PML and major histocompatibility antigen HLA class I expression in high-grade prostate cancer. Cancer Immun 3:2

    Google Scholar 

  3. Smyth MJ, Godfrey DI, Trapani JA (2001) A fresh look at tumor immunosurveillance and immunotherapy. Nat Immunol 2:293–299

    Article  CAS  PubMed  Google Scholar 

  4. Yang Y et al. (2004) Persistent Toll-like receptor signals are required for reversal of regulatory T-cell-mediated CD8 tolerance. Nat Immunol 5:508–515

    Article  Google Scholar 

  5. Abbott Laboratories (2003) One phase III study confirms activity but does not meet primary endpoint; other phase III and phase II studies with Atrasentan continue. Abbott Laboratories, Abbott Park

  6. Saad F et al. (2002) A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94:1458–1468

    Google Scholar 

  7. Small EJ et al. (2003) A randomized, placebo-controlled phase III trial of APC8015 in patients with androgen-independent prostate cancer (AiPCa). Proc Am Soc Clin Oncol 22:382

    Google Scholar 

  8. McNeel DG, Nguyen LD, Disis ML (2001) Identification of T helper epitopes from prostatic acid phosphatase. Cancer Res 61:5161–5167

    Google Scholar 

  9. Halabi S et al. (2003) Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol 21:1232–1237

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Eastern Virginia Medical School and Devine Tidewater Urology, Norfolk, VA, USA

    Paul F. Schellhammer

  2. Dendreon Corporation, Seattle, WA, USA

    Robert M. Hershberg

  3. Interstate Corporate Center, 6333 Center Drive, Bldg 16, Norfolk, VA 23502, USA

    Paul F. Schellhammer

Authors
  1. Paul F. Schellhammer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert M. Hershberg
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Paul F. Schellhammer.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schellhammer, P.F., Hershberg, R.M. Immunotherapy with autologous antigen presenting cells for the treatment of androgen independent prostate cancer. World J Urol 23, 47–49 (2005). https://doi.org/10.1007/s00345-004-0475-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00345-004-0475-z

Keywords

Search

Navigation